Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers

NCT02159716 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT02159716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02159716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers
Lead sponsor
University of Pennsylvania
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2014
Completion date
November 30, 2015
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer, malignant epithelial pleural mesothelioma, metastatic pancreatic (ductal) adenocarcinoma